Survodutide Phase 3 Comes With GI Tolerability Cost & Trevogrumab Trims Lean-Tissue Loss on Scans

Boehringer's survodutide reached up to 13.1% weight loss in Phase 3 assuming patients stayed on treatment, but GI-related dropouts complicate its place in obesity and Type 2 diabetes. CMS's final GLOBE rule tests international prices in Medicare Part B rebates: what changes for patients and doctors? Regeneron's trevogrumab reduced lean-mass loss on scans with semaglutide, without proving greater strength. Also: Sanofi and Regeneron expand their Dupixent alliance with four long-acting antibodies; Foghorn and Lilly stop FHD-909 expansion after insufficient efficacy; and Wave's WVE-006 gets a potential registration path in alpha-1 antitrypsin deficiency.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.